bezisterim

all catalysts(0)

nothing on the calendar yet

News(2)

• BioVie shares halve on murky Parkinson’s disease readout
  BioVie’s stock fell by nearly 50% as the biotech claimed victory in a mid-stage Parkinson’s disease trial using an alternative endpoint to the primary clinical goal.
  biospace · 8d ago
• BioVie’s stock sinks 50% as company uses composite endpoint to make case for Parkinson’s program
  BioVie has hailed phase 2 data as evidence that bezisterim could represent a “meaningful advance” in the treatment of Parkinson’s disease. But the biotech focused on a new composite measure, rather…
  fiercebiotech · 9d ago